Other Information .
+Added: During the quarter ended June 30, 2023, none of our officers or directors adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities that was
+Added: intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act or any “non-Rule 10b5-1 trading arrangement”, as defined in Item 408 of Regulation S-K.
Incorporated By
−Removed: Exclusive License Agreement, dated February 20, 2023, by and between Factor Bioscience Limited and Eterna Therapeutics Inc.
−Removed: Exhibit 10.1 to Form 8-K filed on February 22, 2023
Purchase Agreement, dated as of April 5, 2023, by and between Eterna Therapeutics Inc.
4 unchanged sentences
Exhibit 10.2 to Form 8-K filed on April 11, 2023
+Added: Asset Purchase Agreement, dated April 26, 2023, by and among Eterna Therapeutics Inc., Exacis Biotherapeutics Inc., the stockholders party thereto and, with respect to certain provisions, Factor Bioscience
+Added: Exhibit 10.1 to Form 8-K filed on May 2, 2023
+Added: Separation Agreement and General Release, dated May 2, 2023, by and between Eterna Therapeutics Inc.
+Added: and Andrew Jackson.
+Added: Exhibit 10.1 to Form 8-K filed on May 5, 2023
Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
19 unchanged sentences
Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).
+Added: Indicates management contract or compensatory plan.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ETERNA THERAPEUTICS INC.
+Added: August 11, 2023
/s/ Matthew Angel
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.